Clinical Trial Record

Return to Clinical Trials

ToPanc Trial: Survival After Total Versus Partial Pancreaticoduodenectomy for Adenocarcinoma of the Pancreatic Head, Distal Cholangiocarcinoma, and Ampullary Cancer


2025-05


2029-07


2029-07


170

Study Overview

ToPanc Trial: Survival After Total Versus Partial Pancreaticoduodenectomy for Adenocarcinoma of the Pancreatic Head, Distal Cholangiocarcinoma, and Ampullary Cancer

The goal of this clinical trial is to learn if total removal of the pancreas is a preferable alternative to partial removal in patients with cancer of the pancreatic head who are at high risk of pancreatic leakage. The main question it aims to answer is: Does total pancreas removal improve survival without reducing quality of life compared to partial removal? The only study specific procedures are the collection of 2 blood samples (7.5ml for each time point, preoperatively and during the hospitalisation) and the completion of the questionnaires.

The pancreas is located in the upper abdomen and has 2 main functions: Production of digestive juices and of insulin, the latter being most important for blood sugar regulation and energy conservation. Certain types of cancer in the pancreatic head are very aggressive, but with complete surgical removal of the tumor and additional chemotherapy cure is possible. For tumor resection, the head of the pancreas as well as duodenum and part of the bile duct are removed. 3 new connections are built: the remaining pancreas, bile duct and stomach are connected to a loop of small intestine. This operation takes around 6 hours and leads to complications in 20-30% of cases. A serious complication and unfortunately the most frequent is the leaking of the pancreas remnant, with outflow of the aggressive digestive juice into the surrounding tissue. Consequences may be severe bleeding and/or infections. Many studies show that affected patients have an increased risk of tumor recurrence and a reduced survival. To avoid pancreatic leak, the entire pancreas can be removed. So far, removal of the whole pancreas has only been chosen in cases of very advanced cancer. After both, partial or total pancreas removal, patients need to substitute digestive enzymes. This can be done by capsules, which need to be taken with every meal. But while some patients after partial removal maintain sufficient function to produce insulin, all patients after total removal are diabetic and need insulin injections. In the past, blood sugar control in the absence of insulin production was difficult and accompanied by low quality of life (QoL). This has changed tremendously by the introduction of continuous glucose monitoring (sensors, which are attached to the arm) and automated insulin delivery systems (also known as Ȫrtificial pancreas"). This development renders total pancreas removal a reasonable alternative, with the advantage, that only 2 new connections are made: One between the bile duct and small intestine and one between the stomach and the small intestine. Study question: Is removal of the whole pancreas in patients at high risk of a pancreatic leakage a preferable alternative to partial removal? For this study, patients with cancer of the pancreatic head who are planned for surgery can be included. These patients will be randomly assigned to two groups: 1. Standard group: partial removal of the pancreas 2. Study group: total removal of the pancreas Both techniques are safe and are established techniques to treat cancer in the pancreatic head. After the operation, many clinical data will be recorded. The two most important factors will be survival and quality of life, which will be assessed by questionnaires on a regular base. Additionally, postoperative complications, chemotherapy rates, tumor recurrence and many more data will be monitored.

  • Pancreatic Cancer
  • PROCEDURE: Total pancreatectomy (TP)
  • PROCEDURE: Partial pancreaticoduodenectomy (PD)
  • 2024-02010

Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates Results Reporting Dates Study Record Updates

2025-01-24  

N/A  

2025-04-17  

2025-01-29  

N/A  

2025-04-23  

2025-01-30  

N/A  

2025-04  

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

Design Details

Primary Purpose:
Treatment


Allocation:
Randomized


Interventional Model:
Parallel


Masking:
None


Arms and Interventions

Participant Group/ArmIntervention/Treatment
EXPERIMENTAL: Total pancreatectomy (TP)

PROCEDURE: Total pancreatectomy (TP)

  • The investigators perform TP in patients who undergo surgical resection of a malignant tumor in the pancreatic head.
ACTIVE_COMPARATOR: Pancreaticoduodenectomy (PD)

PROCEDURE: Partial pancreaticoduodenectomy (PD)

  • The investigators perform partial PD with anastomosis of the pancreas in patients who undergo surgical resection of a malignant tumor in the pancreatic head. This is the current standard procedure.
Primary Outcome MeasuresMeasure DescriptionTime Frame
Overall survival (OS)Number of participants who survived for 2 years after surgery.At 2 years
Secondary Outcome MeasuresMeasure DescriptionTime Frame
Quality of Life (QoL) Pancreatic CancerRecorded as participant-reported outcome. Measured by European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire for pancreatic cancer (EORCT QLQPAN26). Scale from 0 to 104, with higher scores indicating a greater level of symptoms or problems.At 0.5 year, at 1 year, at 2 years
Quality of Life (QoL) DiabetesRecorded as participant-reported outcome. Measured by Diabetes Distress Scale (DDS) 17 Questionnaire (only for patients with insulin-dependent diabetes). Scale from 17 to 102, with higher scores indicating a greater level of distress.At 0.5 year, at 1 year, at 2 years
Postoperative complications (discriminating minor and major complications)Number of participants with postoperative complications. Classified according to the Clavien-Dindo-classification (major complication defined as Clavien-Dindo Grade ≥ III).Within 30 day of surgery
MortalityNumber of participants who died.Within 30 days of surgery
Length of hospital stay in daysWithin 30 days of surgery
Re-admissionNumber of participants who were re-admitted to the hospital.Within 30 days of surgery
Re-operationNumber of participants who required a re-operation.Within 30 days of surgery
Adjuvant Chemotherapy (ACT) initiationNumber of days from surgery to ACT initiation.At 1 year
Adjuvant Chemotherapy (ACT) completionNumber of days from surgery to ACT completion.At 1 year
Disease-Free Survival (DFS)Number of participants who remained free of disease. Defined as no new metastasis or local recurrence on CT or MRI imaging, and, if applicable, laboratory tests (new Ca19-9 increase).At follow-up, up to 4.5 years
Functional statusRecorded as participant-reported outcome. Measured by Eastern Cooperative Oncology Group (ECOG) Performance Status Scale. Scale from 1 to 5, with higher scores indicating a greater level of disability.At 0.5 year, at 1 year, at 2 years
Body Mass Index (BMI)At 0.5 year, at 1 year, at 2 years

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Name: Anna S Wenning, MD, PhD

Phone Number: +41 (0)31 632 71 41

Email: annasilvia.wenning@insel.ch

Study Contact Backup

Name: Nadine Uebersax

Phone Number: +41 (0)31 684 33 69

Email: nadine.uebersax@unibe.ch

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person’s general health condition or prior treatments.

Ages Eligible for Study:
ALL

Sexes Eligible for Study:
18 Years

Accepts Healthy Volunteers:

    Inclusion Criteria:

  • Adult patients (age ≥ 18 years) scheduled to undergo PD for highly suspected or histologically proven, resectable pancreatic ductal adenocarcinoma (PDAC), distal cholangiocarcinoma (DCC), and/or ampullary cancer (pancreaticobiliary type)
  • Suspected pancreas anastomosis at high-risk for development of a postoperative pancreatic fistula (POPF) (grade "D" according to Schuh et al. (29): Estimation by CT scan, MRI, and/or Endoscopic Ultrasound
  • Written informed consent

  • Exclusion Criteria:

  • Duodenal carcinoma, ampullary cancer (intestinal type), neuroendocrine tumors, benign tumors, chronic pancreatitis
  • Medical conditions that do not allow appreciation of the nature, scope, and possible consequences of the trial as judged by the investigator
  • Pregnancy. A beta-Human Chorionic Gonadotropin (bHCG) pregnancy test must to be performed for women of child-bearing potential (defined as premenopausal women who have not undergone surgical sterilization)
  • Inability to follow the study procedures, e.g., due to psychological disorders, dementia, etc.

Collaborators and Investigators

This is where you will find people and organizations involved with this study.


    • PRINCIPAL_INVESTIGATOR: Anna S Wenning, MD, PhD, Department of Visceral Surgery and Medicine Inselspital, Bern University Hospital

    Publications

    The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

    General Publications

    No publications available